New-onset diabetes after renal transplantation

Journal of Investigative Medicine

Volumn 58, Issue 6, 2010, Pages 755-763

  Mora, Pablo F ^a  

^a UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

Diabetes after transplantation; Prediction of diabetes after renal graft

Indexed keywords

AZATHIOPRINE; CALCINEURIN INHIBITOR; CYCLOSPORIN A; GLUCOCORTICOID; GLUCOSE; GLYCOSYLATED PROTEIN; HEMOGLOBIN A1C; INSULIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS;

AGE; ANTHROPOMETRY; CARDIOVASCULAR DISEASE; CELL FUNCTION; CLINICAL TRIAL; CORTICOSTEROID THERAPY; CUSHING SYNDROME; DEMOGRAPHY; DIABETES MELLITUS; DRUG PROTEIN BINDING; ETHNICITY; GENETIC POLYMORPHISM; GLUCOSE METABOLISM; GRAFT SURVIVAL; HEPATITIS C; HIGH RISK POPULATION; HUMAN; HYPERGLYCEMIA; IMMUNOSUPPRESSIVE TREATMENT; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; KIDNEY FAILURE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MEDICAL PRACTICE; METABOLIC SYNDROME X; NEW ONSET DIABETES AFTER TRANSPLANTATION; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET BETA CELL; PANCREATITIS; PATHOPHYSIOLOGY; PREDICTION; REVIEW; RISK FACTOR;

HEPATITIS C VIRUS;

EID: 77957998941     PISSN: 17088267     EISSN: None     Source Type: Journal    
DOI: 10.2310/JIM.0b013e3181e61a64     Document Type: Review

References (103)

1. Arner P, Gunnarsson R, Blomdahl S, et al. Some characteristics of steroid diabetes: a study in renal-transplant recipients receiving high-dose corticosteroid therapy. Diabetes Care. 1983;6:23-25.
2. Chow KM, Li PK. Review article: new-onset diabetes after transplantation. Nephrology (Carlton). 2008;13:737-744.
3. Montori VM, Basu A, Erwin PJ, et al. Posttransplantation diabetes: a systematic review of the literature. Diabetes Care. 2002;25:583-592.
4. Mora P. Post-transplantation diabetes mellitus. Am J Med Sci. 2005;329(2):86-94.
5. Pavlakis M. New onset diabetes after transplantation. Curr Diab Rep. 2005;5:300-304.
6. Driscoll C. Risk factors for posttransplant diabetes mellitus: a review of the literature. Prog Transplant. 2007;17(4):295-300.
7. Bloom RD, Crutchlow MF. Transplant-associated hyperglycemia. Transplant Rev. 2008;22:39-51.
8. Balla A, Chobanian M. New-onset diabetes after transplantation: a review of recent literature. Curr Opin Organ Transplant. 2009;14:375-379.
9. Gomes MB, Cobas RA. Post-transplant diabetes mellitus. Diabetol Metab Syndr. 2009;1:14-21.
10. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2010;33: S62-S69.
11. Haider DG, Mittermayer F, Friedl A. Postprandial blood glucose level in maintenance hemodialysis predicts post-transplant diabetes mellitus. Exp Clin Endocrinol Diabetes. 2010;118:200-204.
12. Ruiz JO, Simmons RL, Callender CO, et al. Steroid diabetes in renal transplant recipients: pathogenic factors and prognosis. Surgery. 1973;73:759-765.
13. Woodward RS, Schnitzler MA, Baty J, et al. Incidence and cost of new onset diabetes mellitus among U. S. wait-listed and transplanted renal allograft recipients. Am J Transplant. 2003;3(5):590-598.
14. Kasiske BL, Snyder JJ, Gilbertson D, et al. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant. 2003;3:178-185.
15. Valderhaug TG, Hjelmesaeth J, Rollag H, et al. Reduced incidence of new-onset posttransplantation diabetes mellitus during the last decade. Transplantation. 2007;84:1125-1130.
16. Davidson J, Wilkinson A, Dantal J, et al. New-onset diabetes after transplantation: 2003 international consensus guidelines. Transplantation. 2003;75: SS3-SS25.
17. Moore R, Boucher A, Carter J, et al. Diabetes mellitus in transplantation: 2002 consensus guidelines. Transplant Proc. 2003;35:1265-1270.
18. Wilkinson A, Davidson J, Dotta F, et al. Guidelines for the treatment and management of new-onset diabetes after transplantation. Clin Transplan. 2005;19:291-298.
19. Mathew JT, Rao M, Job V, et al. Post-transplant hyperglycaemia: a study of risk factors. Nephrol Dial Transplant. 2003;18:164-171.
20. Hur KY, Kim MS, Kim YS, et al. Risk factors associated with the onset and progression of posttransplantation diabetes in renal allograft recipients. Diabetes Care. 2007;30:609-615.
21. Boschiero L, Fior F, Nacchia F. Bimodal distribution of major cardiovascular event in renal allograft recipients. Transplant Proc. 2009;41:1181-1186.
22. Bayés B, Granada ML, Pastor MC, et al. Obesity, adiponectin and inflammation as predictors of new-onset diabetes mellitus after kidney transplantation. Am J Transplant. 2006;7:416-422.
23. Nishimura K, Kishikawa H, Kato T, et al. Tacrolimus and angiotensin receptor blockers associated with changes in serum adiponectin level in new-onset diabetes after renal transplantation: single-center cross-sectional analysis. Transplant Int. 2009;22:694-701.
24. Kato K, Matsuhisa M, Ichimaru N, et al. The impact of new onset diabetes on arterial stiffness after renal transplantation. Endocr J. 2008;55:677-683.
25. Faenza A, Fuga G, Nardo B, et al. Metabolic syndrome after kidney transplantation. Transplant Proc. 2007;39:1843-1846.
26. Kimak E, Solski J, Baranowicz-Gaszczyk I, et al. A long-term study of dyslipidemia and dyslipoproteinemia in stable post-renal transplant patients. Ren Fail. 2006;28:483-486.
27. Neylan JF. Effect of race and immunosuppression in renal transplantation: three-year survival results from a US multicenter, randomized trial. FK506 Kidney Transplant Study Group. Transplant Proc. 1998;30:1355-1358.
28. Revanur VK, Jardine AG, Kingsmore DB, et al. Influence of diabetes mellitus on patient and graft survival in recipients of kidney transplantation. Clin Transplant. 2001;15:89-94.
29. Aker S, Ivens K, Grabensee B, et al. Cardiovascular risk factors and diseases after renal transplantation. Int Urol Nephrol. 1998;30(6):777-788. (Pubitemid 29125544)
30. Cosio FG, Kudva Y, van der Velde M, et al. New onset hyperglycemia and diabetes are associated with increased cardiovascular risk after kidney transplantation. Kidney Int. 2005;67:2415-2421.
31. Miles AM, Sumrani N, Horowitz R, et al. Diabetes mellitus after renal transplantation. Transplantation. 1998;65:380-384.
32. Meyer C, Gerich J. Role of the kidney in hyperglycemia in type 2 diabetes. Curr Diab Rep. 2002;2:236-241.
33. Chen J, Muntner P, Hamm LL, et al. Insulin resistance and risk of chronic kidney disease in nondiabetic US adults. J Am Soc Nephrol. 2003;14:469-477.
34. DeFronzo RA, Tobin JD, Rowe JW, et al. Glucose intolerance in uremia. J Clin Invest. 1978;62:425-435.
35. DeFronzo RA, Alvestrand A, Smith D, et al. Insulin resistance in uremia. J Clin Invest. 1981;67:563-568.
36. Massry SG. Insulin secretion in uremia. Am J Kidney Dis. 2001;38: S58-S62.
37. Fernandez-Real JM, Lopez-Bermejo A, Ricart W. Cross-talk between iron metabolism and diabetes. Diabetes. 2002;51:2348-2354.
38. Mak RH. Insulin resistance in uremia: effect of dialysis modality. Pediatr Res. 1996;40:304-308.
39. + ATPase of pancreatic islets in chronic renal failure: role of secondary hyperparathyroidism. J Am Soc Nephrol. 1992;2:1355-1359.
40. Fliser D, Pacini G, Engelleiter R, et al. Insulin resistance and hyperinsulinemia are already present in patients with incipient renal disease. Kidney Int. 1998;53:1343-1347.
41. Ritz E, Koleganova N. Obesity and chronic kidney disease. Semin Nephrol. 2009;29:504-511.
42. Porrini E, Delgado P, Alvarez A, et al. The combined effect of pre-transplant triglyceride levels and the type of calcineurin inhibitor in predicting the risk of new onset diabetes after renal transplantation. Nephrol Dial Transplant. 2008;23:1436-1441.
43. Markell MS, Armenti V, Danovitch G, et al. Hyperlipidemia and glucose intolerance in the post-renal transplant patient. J Am Soc Nephrol. 1994;4: S37-S47.
44. Caronia S, Taylor K, Pagliaro L, et al. Further evidence for an association between non-insulin-dependent diabetes mellitus and chronic hepatitis C virus infection. Hepatology. 1999;30:1059-1063.
45. Mason AL, Lau JY, Hoang N, et al. Association of diabetes mellitus and chronic hepatitis C virus infection. Hepatology. 1999;29:328-333.
46. Mehta SH, Brancati FL, Sulkowski MS, et al. Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the Unites States. Ann Intern Med. 2000;133:592-599.
47. Petit JM, Bour JB, Galland-Jos C, et al. Risk factors for diabetes mellitus and early insulin resistance in chronic hepatitis C. J Hepatol. 2001;35:279-283.
48. Yildiz A, Tütüncü Y, Yazici H, et al. Association between hepatitis C virus infection and development of posttransplantation diabetes mellitus in renal transplant recipients. Transplantation. 2002;74:1109-1113.
49. Lipshutz AK, Gropper MA. Perioperative glycemic control. Anesthesiology. 2009;110:408-421.
50. van den Berg TJ, Bogers H, Vriesendorp TM, et al. No apparent impact of increased post-operative blood glucose levels on clinical outcome in kidney transplant recipients. Clin Transplant. 2009;23:256-263.
51. Vazquez MA. New advances in immunosuppression therapy for renal transplantation. Am J Med Sci. 1997;314:415-435.
52. Conn JW, Fajans SS. Influence of adrenal cortical steroids on carbohydrate metabolism in man. Metabolism. 1956;5:114-127.
53. McKiddie MT, Jasani MK, Buchanan KD, et al. The relationship between glucose tolerance, plasma insulin and corticosteroid therapy in patients with rheumatoid arthritis. Metabolism. 1968;17:730-739.
54. Burroughs TE, Lentine KL, Takemoto SK, et al. Influence of early posttransplantation prednisone and calcineurin inhibitor dosages on the incidence of new onset diabetes. Clin J Am Soc Nephrol. 2007;2:517-523.
55. Jaber JJ, Feustel PJ, Elbahloul O, et al. Early steroid withdrawal therapy in renal transplant recipients: a steroid-free sirolimus and mycophenolate mofetil-based calcineurin-minimization protocol. Clin Transplant. 2007;21:101-109.
56. Kim YS, Kim MS, Kim SI, et al. Post-transplantation diabetes is better controlled after conversion from prednisone to deflazacort: a prospective trial in renal transplants. Transplant Int. 1997;10:197-201.
57. Tornatore KM, Biocevich DM, Reed KA, et al. Post-transplant diabetes mellitus and methylprednisolone pharmacokinetics in African-American and Caucasian renal transplant recipients. Clin Transplant. 1995;9:289-296.
58. Yabu JM, Vincenti F. Kidney transplantation: the ideal immunosuppression regimen. Adv Chronic Kidney Dis. 2009;16(4):226-233.
59. Martin F, Bedoya FJ. Mechanisms of action of cyclosporin A on islet alpha and beta cell effects on cAMP-and calcium-dependent pathways. Life Sci. 1991;49:1915-1921.
60. Marchetti P, Navalesi R. The metabolic effects of cyclosporin and tacrolimus. J Endocrinol Invest. 2000;23:482-490.
61. Ricordi C, Zeng YJ, Alejandro R, et al. In vivo effect of FK506 on human pancreatic islets. Transplantation. 1991;52:519-522.
62. Hirano Y, Fujihira S, Ohara K, et al. Morphological and functional changes of islets of Langerhans in FK506-treated rats. Transplantation. 1992;53:889-894.
63. Bani-Sacchi T, Bani D, Filipponi F, et al. Immunocytochemical and ultrastructural changes of islet cells in rats treated long-term with cyclosporine at immunotherapeutic doses. Transplantation. 1990;49:982-987.
64. van Hooff JP, Christiaans MH, van Duijnhoven EM. Evaluating mechanisms of post-transplant diabetes mellitus. Nephrol Dial Transplant. 2004;19(6): VI8-VI12.
65. Vincenti F, Friman S, Scheuermann E, et al. Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. Am J Transplant. 2007;7:1506-1514.
66. Lee YJ, Kim B, Lee JE, et al. Randomized trial of cyclosporine and tacrolimus therapy with steroid withdrawal in living-donor renal transplantation: 5-year follow-up. Transplant Int. 2009.
67. Ersoy A, Baran B, Ersoy C, et al. Calcineurin inhibitors and post-transplant weight gain. Nephrology. 2008;13:433-439.
68. Penfornis A, Kury-Paulin S. Immunosuppressive drug-induced diabetes. Diabetes Metab. 2006;32:539-546.
69. Pavlakis M, Goldfarb-Rumyantzev AS. Diabetes after transplantation and sirolimus: what's the connection? J Am Soc Nephrol. 2008;19:1255-1256.
70. Weir MR, Wali RK. Optimizing immunosuppression with sirolimus in the first year posttransplantation: experience in the United States. Transplant Proc. 2009;41: S13-S17.
71. Stern MP, Williams K, Haffner SM. Identification of persons at high risk for type 2 diabetes mellitus: do we need the oral glucose tolerance test? Ann Intern Med. 2002;136:575-581. (Pubitemid 34407041)
72. Emoto M, Nishizawa Y, Maekawa K, et al. Homeostasis model assessment as a clinical index of insulin resistance in type 2 diabetic patients treated with sulfonylureas. Diabetes Care. 1999;22:818-822.
73. Bonora E, Targher G, Alberiche M, et al. Homeostasis model assessment closely mirror the glucose clamp technique in the assessment of insulin sensitivity. Diabetes Care. 2000;23:57-63.
74. Ferrara CM, Goldberg AP. Limited value of the homeostasis model assessment to predict insulin resistance in older men with impaired glucose tolerance. Diabetes Care. 2001;24:245-249.
75. Katsuki A, Sumida Y, Gabazza EC, et al. Homeostasis model assessment is a reliable indicator of insulin resistance during follow-up of patients with type 2 diabetes. Diabetes Care. 2001;24:362-365.
76. Bonora E, Formentini G, Calcaterra F, et al. HOMA-estimated insulin resistance is an independent predictor of cardiovascular disease in type 2 diabetic subjects. Diabetes Care. 2002;25:1135-1141.
77. Hanley AJ, Williams K, Stern MP, et al. Homeostasis model assessment of insulin resistance in relation to the incidence of cardiovascular disease. Diabetes Care. 2002;25:1177-1184.
78. Levy JC, Matthews DR, Hermans MP. Correct homeostasis model assessment (HOMA) evaluation uses the computer program. Diabetes Care. 2002;21:2191-2192.
79. Shehab-Eldin W, Shoker A. Predictors of new onset of diabetes after transplantation in stable renal recipients. Nephrol Clin Pract. 2008;110: c1-c9.
80. Joss N, Staatz CE, Thomson AH, et al. Predictors of new onset diabetes after renal transplantation. Clin Transplant. 2007;19:136-143.
81. Kuypers DR, Claes K, Bammens B, et al. Early clinical assessment of glucose metabolism in renal allograft recipients: diagnosis and prediction of post-transplant diabetes mellitus (PTDM). Nephrol Dial Transplant. 2008;23:2033-2042.
82. Armstrong KA, Prins JB, Beller EM, et al. Should an oral glucose tolerance test be performed routinely in all renal transplant recipients? Clin J Am Soc Nephrol. 2006;1:100-108.
83. Sharif A, Moore RH, Baboolal K. The use of oral glucose tolerance tests to risk stratify for new-onset diabetes after transplantation: an underdiagnosed phenomenon. Transplantation. 2006;82:1667-1672.
84. A1c: how do we measure it and what does it mean? Curr Opin Endocrinol Diabetes Obes. 2009;16:113-118.
85. International Expert Committee. International Expert Committee report on the role of the A1c assay in the diagnosis of diabetes. Diabetes Care. 2009;32(7):1327-1334.
86. Cox ME, Edelman D. Tests for screening and diagnosis of type 2 diabetes. Clin Diabetes. 2009;27(4):132-138.
87. Fonseca V, Inzucchi SE, Ferrannini E. Redefining the diagnosis of diabetes using glycated hemoglobin. Diabetes Care. 2009;32:1344-1345.
88. Mitka M. Hemoglobin A1c poised to become preferred test for diagnosing diabetes. JAMA. 2009;301(15):1528.
89. 1c will impact clinical laboratories. Clin Chem. 2009;55(9).
90. Winkelmayer WC, Chandraker A. Posttransplantation anemia: management and rationale. Clin J Am Soc Nephrol. 2008;3: S49-S55.
91. Chujo K, Shima K, Tada H, et al. Indicators for blood glucose control in diabetics with end-stage chronic renal disease: GHb vs glycated albumin (GA). J Med Invest. 2006;53:223-228.
92. A1c in the detection of subclinical post renal transplant diabetes. Transplantation. 2006;8:379-383.
93. Valderhaug TG, Jenssen T, Hartmann A, et al. Fasting plasma glucose and glycosylated hemoglobin in the screening for diabetes mellitus after renal transplantation. Transplantation. 2009;88:429-434.
94. Hathaway DK, Tolley EA, Blakely ML, et al. Development of an index to predict posttransplant diabetes mellitus. Clin Transplant. 1993;7:330-338.
95. Ghisdal L, Baron C, Le Meur Y, et al. TCF7L2 polymorphism associates with new-onset diabetes after transplantation. J Am Soc Nephrol. 2009;20:2459-2467.
96. Anil Kumar MS, Irfan Saeed M, Ranganna K, et al. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five year outcomes. Transpl Immunol. 2008;20:32-42.
97. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes mellitus with lifestyle intervention or metformin. N Engl J Med. 2002;346:393-403.
98. DREAM Trial Investigators, Bosch J, Yusuf S, et al. Effect of ramipril on the incidence of diabetes. N Engl J Med. 2006;355:1551-1562.
99. DREAM Trial Investigators, Dagenais GR, Gerstein HC, et al. Effects of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucose: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial. Diabetes Care. 2008;31:1007-1014.
100. Guida B, Trio R, Laccetti R, et al. Role of dietary intervention on metabolic abnormalities and nutritional status after renal transplantation. Nephrol Dial Transplant. 2007;22:3304-3310.
101. Sharif A, Moore R, Baboolal K. Influence of lifestyle modification in renal transplant recipients with postprandial hyperglycemia. Transplantation. 2008;85:353-358.
102. Jezior D, Krajewska M, Madziarska K, et al. Weight reduction in renal transplant recipients program: the first successes. Transplant Proc. 2007;39:2769-2771.
103. Marterre WF, Hariharan S, First MR, et al. Gastric bypass in morbidly obese kidney transplant recipients. Clin Transplant. 1996;10:414-419.